Successful Sequential and Additive Drug Challenge With Rapid Oral Desensitization in Rifampicin‐Induced Fever Authors: Xin Yue Guo, Constantine Zois Published: 2026 ABSTRACT ABSTRACTAdverse drug reactions to first‐line antituberculosis (anti‐TB) therapy are common and may necessitate treatment interruption. While drug desensitization is increasingly used for delayed hypersensitivity, evidence supporting outpatient rapid oral desensitization in mild delayed reactions such as drug‐induced fever is limited. We report a 63‐year‐old man with active pulmonary tuberculosis who developed drug‐induced fever after commencing standard anti‐TB therapy. Sequential and additive drug challenge identified rifampicin as the offending agent. The patient subsequently underwent successful rapid oral rifampicin desensitization in an outpatient setting, enabling completion of 6 months of therapy without recurrence of adverse effects. This case demonstrates the feasibility of outpatient rapid oral desensitization for mild delayed hypersensitivity reactions, including drug‐induced fever. Such an approach may reduce treatment interruption and hospitalisation, particularly in settings where standardised outpatient desensitization protocols are lacking. Further studies are needed to define optimal strategies for managing mild delayed hypersensitivity reactions to anti‐TB medications. Introduction First‐line antituberculosis (anti‐TB) therapy consists of isoniazid (INH), rifampicin (RIF), ethambutol (EMB) and pyrazinamide (PZA), all of which are commonly associated with adverse drug reactions. Some reactions are direct consequences of drug metabolites or mechanisms of action, such as isoniazid‐ and pyrazinamide‐induced hepatotoxicity, pyrazinamide‐associated hyperuricaemia and ethambutol‐induced optic neuropathy [1]. Other reactions are due to drug‐hypersensitivity and may be IgE‐mediated, including urticaria, angioedema, bronchospasms and anaphylaxis, or non‐IgE mediated. Non‐IgE mediated reactions, also referred to as delayed hypersensitivity reactions, have heterogenous clinical presentations, including but not limited to maculopapular drug eruptions (MPE), drug‐induced fever, Stevens‐Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) [2]. Drug desensitization may be considered when alternative non‐cross‐reacting drug cannot be prescribed and continuation of therapy is essential [3]. Several protocols have been reported for managing delayed hypersensitivity reactions in TB (Table 1); however, no standardized protocol has been published in Australia. Evidence supporting desensitization specifically for drug‐induced fever is limited. We report a case of successful sequential and additive drug challenge (SADC) with rapid oral desensitization in a patient with active pulmonary TB complicated by drug‐induced fever. TABLE 1Summary of desensitization protocols for delayed hypersensitivity reactions induced by anti‐TB medications.StudyYearStudy siteType of studyNumber of casesDesensitization protocolsStarting dose and dose incrementationIncrement intervalsSuccess rate of desensitizationTypes of TBBulut et al. [4]2024TurkeyRetrospective cohort study41Rapid oral desensitization protocol7.5 mg INH, 10 mg RIF, 5 mg EMB, 10 mg PZA sequential addition after each escalated to full dose and maintained for 5 days30 min–5 days46.3% (19/41) 34 Pulmonary TB 7 Extrapulmonary Ban et al. [5]2019South KoreaProspective cohort study12Rapid oral desensitization protocol0.5 mg INH, 0.8 mg EMB, 1 mg RIF and 5 mg PZA then 2‐fold increase15 min80.7% (25/31) 8 Pulmonary TB 4 Extrapulmonary TB Siripassorn et al. [6]2018ThailandRetrospective cohort study13Rapid oral desensitization protocol0.0003 mg RIF then 3‐fold, then 10‐fold respectively.9–15 h78.9% (15/19)6 Pulmonary TBRoy et al. [7]2018United StatesCase report1Rapid oral desensitization protocol0.1 mg RIF and 0.5 mg INH then 2‐fold increase30 minNACentral Nervous System (CNS) TBLee et al. [8]2015South KoreaCase report1Rapid oral desensitization protocol 0.0002 mg RIF then 10‐fold increase. 0.0001 mg INH then 0.5 mg then 2‐fold increase 30 minNAPulmonary TBThong et al. [3]2014SingaporeRetrospective cohort study11Multiday oral desensitization protocol0.1 mg RIF or 0.1 mg INH, then 0.5 mg6–24 h92% (23/25) 6 Pulmonary TB 2 Extrapulmonary TB 3 Pulmonary and extrapulmonary TB Kobashi et al. [9]2010JapanRetrospective cohort study46Multiday oral desensitization protocol (JST, 1997) [10] 25 mg of RIF and 25 mg INH then doubled 72 h77% RIF (23/30) and 88% for INH (13/16) 28 Pulmonary TB 11 Non‐TB Mycobaacterium (NTM) 6 Extrapulmonary TB 1 Pulmonary and extrapulmonary TB Kura and Hira [11]2001IndiaProspective observational study8Multiday oral desensitization50 mg INH, 200 mg EMB, 150 mg RIF and 250 mg PZA introduced sequentially and gradually increased by 50‐100 mg every 2 days48 h87.5% (7/8)8 Pulmonary TBMatz et al. [12]1994United StatesCase series10Rapid oral desensitization0.1 mg RIF and 0.1 mg EMB then 0.5 mg followed by 2‐fold increase45 min100% 9 Pulmonary MAC 1 Pulmonary Mycobaterium kansasii infection Holland et al. [13]1990United StatesCase report1Rapid oral desensitization 0.1 mg RIF and 0.1 mg INH then 0.5 mg followed by 2‐fold increase 15 minNAPulmonary TBAbbreviations: EMB, ethambutol; INH, isoniazid; PZA, pyrazinamide; RIF, rifampicin. Summary of desensitization protocols for delayed hypersensitivity reactions induced by anti‐TB medications. 34 Pulmonary TB 7 Extrapulmonary 8 Pulmonary TB 4 Extrapulmonary TB 0.0002 mg RIF then 10‐fold increase. 0.0001 mg INH then 0.5 mg then 2‐fold increase 6 Pulmonary TB 2 Extrapulmonary TB 3 Pulmonary and extrapulmonary TB 25 mg of RIF and 25 mg INH then doubled 28 Pulmonary TB 11 Non‐TB Mycobaacterium (NTM) 6 Extrapulmonary TB 1 Pulmonary and extrapulmonary TB 9 Pulmonary MAC 1 Pulmonary Mycobaterium kansasii infection 0.1 mg RIF and 0.1 mg INH then 0.5 mg followed by 2‐fold increase Abbreviations: EMB, ethambutol; INH, isoniazid; PZA, pyrazinamide; RIF, rifampicin. Case Report A 63‐year‐old tax administration officer presented with a five‐week history of productive cough, cyclical fevers, anorexia and unintentional weight loss. His medical history included quiescent Crohn's disease treated with upadacitinib, chronic hepatitis B managed with tenofovir, asthma, metabolic syndrome and a right adrenal adenoma. Eighteen months prior to presentation, he was investigated for pulmonary nodules and tree‐in‐bud changes on computed tomography (CT) and bronchoscopy with lavage. Bronchial lavage demonstrated negative microbiology including TB cultures. Pulmonary sarcoidosis was initially considered. Upadacitinib was commenced 3 months prior to presentation, without pre‐treatment QuantiFERON‐TB Gold testing. Subsequent testing demonstrated results consistent with latent TB infection. On day 3 of admission, repeat bronchoscopy revealed TB‐positive bronchial washings. He was commenced on fixed‐dose combination (FDC) therapy (RIF/INH/PZA/EMB 150 mg–75 mg–400 mg–275 mg), 4 tablets daily and discharged to home isolation. Ten days after treatment initiation, he re‐presented to the emergency department with fever, vomiting and diarrhoea. Investigations revealed low procalcitonin and c‐reactive protein levels, negative stool cultures and biliary sludge without evidence of acute cholecystitis or colitis on abdominal CT. Anti‐TB therapy was withheld for 48 h, followed by outpatient SADC under close supervision with daily nursing and medical telehealth reviews. EMB was introduced at 800 mg without febrile reaction over 48 h. PZA 1500 mg with pyridoxine was added for 5 days without adverse effects. RIF was commenced, resulting in fever up to 39°C within 24 h, and was subsequently ceased. The patient remained afebrile for 48 h, after which INH was reintroduced and tolerated for 72 h. Rifampicin was later initiated at 50 mg daily and increased to 600 mg over 6 days using a rapid oral desensitization protocol. (Table 2.) He successfully tolerated full dose FDC therapy following desensitization and completed six months of anti‐TB treatment. TABLE 2Sequential and additive drug challenge (SADC) and graded drug challenge used to desensitize rifampicin‐induced fever.DaysMedications reintroduced (doses)1Ethambutol 800 mg2Ethambutol 800 mg3Ethambutol 800 mgPyrazinamide 1500 mg4Ethambutol 800 mgPyrazinamide 1500 mg5Ethambutol 800 mgPyrazinamide 1500 mg6Ethambutol 800 mgPyrazinamide 1500 mg7Ethambutol 800 mgPyrazinamide 1500 mg8Ethambutol 800 mgPyrazinamide 1500 mg9Ethambutol 800 mgPyrazinamide 1500 mgRifampicin 600 mg10Ethambutol 800 mgPyrazinamide 1500 mgRifampicin ceased11Ethambutol 800 mgPyrazinamide 1500 mg12Ethambutol 800 mgPyrazinamide 1500 mg13Ethambutol 800 mgPyrazinamide 1500 mg14Ethambutol 800 mgPyrazinamide 1500 mg15Ethambutol 800 mgPyrazinamide 1500 mgIsoniazid 300 mg16Ethambutol 800 mgPyrazinamide 1500 mgIsoniazid 300 mg17Ethambutol 800 mgPyrazinamide 1500 mgIsoniazid 300 mg18Ethambutol 800 mgPyrazinamide 1500 mgRifampicin 50 mgIsoniazid 300 mg19Ethambutol 800 mgPyrazinamide 1500 mgRifampicin 100 mgIsoniazid 300 mg20Ethambutol 800 mgPyrazinamide 1500 mgRifampicin 150 mgIsoniazid 300 mg21Ethambutol 800 mgPyrazinamide 1500 mgRifampicin 200 mgIsoniazid 300 mg22Ethambutol 800 mgPyrazinamide 1500 mgRifampicin 300 mgIsoniazid 300 mg23Ethambutol 800 mgPyrazinamide 1500 mgRifampicin 600 mgIsoniazid 300 mg Sequential and additive drug challenge (SADC) and graded drug challenge used to desensitize rifampicin‐induced fever. Discussion Drug desensitization has traditionally been used for IgE‐mediated immediate hypersensitivity, inducing temporary drug tolerance through gradual dose escalation resulting in mast cell hypoactivation [14]. More recently, its application has expanded to include selected delayed hypersensitivity reactions [15]. Desensitization has generally been contraindicated in patients with severe or life‐threatening delayed drug hypersensitivity reactions such as SJS, Toxic Epidermal Necrolysis (TEN) and DRESS [2]. However, emerging evidence suggests it may be cautiously considered when therapeutic benefits outweigh potential risks [5]. Rapid desensitization protocols, often commencing at doses as low as 0.0002 mg with short escalation intervals, have been utilised in severe cutaneous delayed hypersensitivity under close monitoring. In contrast, the Japanese Society of Tuberculosis (JST) protocol, introduced in 1997, employs a higher starting dose and slower escalation approach, reintroducing RIF and INH at 25 mg daily with dose escalation every 3 days until target doses are achieved [10]. Evidence supporting desensitization for anti‐TB drug‐induced fever remains limited. A Japanese study demonstrated success rates of 77% for RIF and 81% for INH using the JST protocol in patients with non‐severe delayed hypersensitivity reactions, including resolution of drug‐induced fever in 11 of 16 patients. The longer dosing intervals were postulated to be beneficial for drugs with longer pharmacokinetics, such as INH and RIF. A longer interval between drug cessation and desensitization was also associated with improved outcomes [9]. A case report from the United States described successful INH desensitization in a patient with drug‐induced fever, measles‐like rash and arthralgia; however, prolonged high‐dose prednisone was required, exposing the patient to significant adverse effects [13]. A retrospective cohort study reported a 92% success rate using a multi‐day oral desensitization protocol in patients with drug‐induced fever and concurrent MPE, eosinophilia or hepatitis, though such protocols may be unnecessarily prolonged for patients with isolated drug‐induced fever [3]. Our protocol is conceptually similar to the JST approach, with a higher starting dose and shorter dose escalation intervals. It allows for outpatient desensitization with more rapid reintroduction of therapy, thereby reducing treatment interruption. Given the limited evidence for desensitization in mild delayed hypersensitivity reactions such as isolated drug‐induced fever, larger prospective studies are needed to validate its safety and effectiveness. Our approach aims to safely manage mild delayed anti‐TB drug hypersensitivity in the outpatient setting while minimizing hospitalizations. Funding The authors have nothing to report. Consent The authors declare that written informed consent was obtained for the publication of this manuscript and accompanying images using the consent form provided by the journal. Conflicts of Interest The authors declare no conflicts of interest.